CA
NZ
UK
AU
IND
US
VSEE HEALTH, INC. Has announced new financing agreements with institutional investors, marking a significant development in the company's growth strategy. This financing move is expected to boost the company's financial position in the healthcare sector.
Vor Biopharma Inc. (NASDAQ: VOR) has announced a recent update to its board of directors. The company welcomed a new independent Class II director while noting the departure of a current board member. This transition aligns with the company’s ongoing efforts to refine its …
Aspira Women's Health Inc. (NASDAQ: AWHL) disclosed that its chief executive vacated the position on June 17, 2026. To maintain operational continuity, the board promptly appointed Jack Fraser as interim chief executive, tasking him with overseeing day‑to‑day activities while a search for a permanent …
Conexeu Sciences Inc. (NASDAQ: CNXU) has reached a pivotal milestone in its push into medical aesthetics. The company announced the completion of its preclinical study, reinforcing its CXU™ platform’s potential in a fast-growing market.
LifeStance Health Group, Inc. (NASDAQ: LFST) disclosed a sudden change to its board composition on July 2, 2026. The filing noted the immediate exit of one director and the addition of three new members, marking a notable shift in governance structure.
Prime Medicine resolves key legal challenge Prime Medicine (NASDAQ: PRME) has overcome a significant legal obstacle in its development pipeline after an arbitration tribunal ruled in its favor against Beam Therapeutics. The decision confirms the company’s rights to advance PM647, its experimental treatment for …
VSEE HEALTH, INC. Has announced new financing agreements with institutional investors, marking a significant development in the company's growth strategy. This financing move is expected to boost the company's financial position in the healthcare sector.
GMR Solutions Inc. (NYSE: GMRS) has bolstered its board with two new independent directors, tapping executives with decades of healthcare experience. The appointments of Dr. Amar Desai and Ellen Zane took effect July 1, 2026, as disclosed in a regulatory filing.
Oncology Institute entered into a loan agreement with OrbiMed Opportunities (CA) V LLC serving as the lead lender. The facility, aggregating a principal amount of $75 million, was drawn in full at closing, delivering immediate capital to support the company’s debt restructuring strategy. The …
Seres Therapeutics, Inc. (NASDAQ: MCRB) announced that its SER-155 program generated encouraging early data in a trial targeting immune‑related colitis. The company released a corporate presentation alongside the results, underscoring the therapeutic potential of a microbiome‑based approach that avoids systemic steroids.
Please wait processing your request...